Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07285694 · ClinicalTrials.gov registry record · Phase 1
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC), sponsored by Arsenal Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 190
- Enrollment target
- 3
- Study locations
NCT07285694: Recruiting Phase 1 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC), sponsored by Arsenal Biosciences.
NCT07285694 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC) that is actively recruiting participants, run by Arsenal Biosciences. The registered enrollment target is 190 participants, below the 401-participant average among 15 other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target (53% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07285694, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC), is actively recruiting participants, sponsored by Arsenal Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 190 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
Primary Outcome
To assess safety and tolerability of increasing dose levels of AB-3028 in successive cohorts of subjects with metastatic CRPC to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of AB-3028
Conditions Studied
Interventions
- BIOLOGICAL AB-3028
Study Locations (3)
California
- City of Hope - Duarte
Iowa
- University of Iowa and Holden Comprehensive Cancer Center - Iowa City
New York
- Perlmutter Cancer Center - NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2026-01-09 |
| Est. Completion | 2031-05 |
| Phase | Phase 1 |
What NCT07285694 shows while recruiting
NCT07285694 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, below the 401-participant average among 15 other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer (mCRPC) appearing as the primary indexed condition, and to 1 intervention - of which AB-3028 is the first listed.
NCT07285694 reports a single indexed study location in California, Iowa, New York.
Frequently Asked Questions
What is clinical trial NCT07285694 about?
NCT07285694 is a clinical study titled "AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)". This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
What is the current status of trial NCT07285694?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 190 participants. The study started on 2026-01-09. Estimated completion is 2031-05.
What conditions does trial NCT07285694 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC).
What interventions are being tested in trial NCT07285694?
The interventions under investigation include: AB-3028 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07285694?
This trial is sponsored by Arsenal Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07285694 being conducted?
This trial has 3 study locations across California, Iowa, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07285694's enrollment target sits among peer trials
190 10th of 15 higher than 6 of 15 other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
RECRUITING · Phase 1
-
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
RECRUITING · Phase 1
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
RECRUITING · Phase 1
-
A Study of NX-1607 in Adults With Advanced Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03257033 · 190 participants · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- NCT03642028 · 190 participants · Phase 4
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- NCT04015609 · 190 participants · NA
Psychotherapy Intervention for Latinos With Advanced Cancer
- NCT04284397 · 190 participants · Early Phase 1
Identification of Critical Thermal Environments for Aged Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI